Slon-Usakiewicz Jacek J, Ng William, Foster J Estelle, Dai Jin-Rui, Deretey Eugen, Toledo-Sherman Leticia, Redden Peter R, Pasternak Andrew, Reid Neil
Protana, Inc., Lead Discovery and Optimization Division, 251 Attwell Drive, Toronto, Ontario M9W 7H4, Canada.
J Med Chem. 2004 Oct 7;47(21):5094-100. doi: 10.1021/jm049733a.
FAC-MS offers a convenient method for measuring the relative binding strengths of ligands in a mixture and enables a rapid ranking and identification of ligands in the mixture as potential hits against immobilized targets. Using immobilized EphB2 receptor tyrosine kinase as the target and known kinase inhibitors, the results of FAC-MS screening (% shift) have been shown to correlate with the binding constant, K(d), and with IC(50) results from the more traditional ELISA assay. Therefore, since FAC-MS can accommodate a wide variety of target proteins, its applications could play a broad role in drug discovery not only at the hit discovery stage but also during the subsequent more rigorous screening at the hit-to-lead and lead optimization stages.
荧光激活细胞分选质谱联用技术(FAC-MS)提供了一种便捷的方法来测量混合物中配体的相对结合强度,并能够快速对混合物中的配体进行排序和鉴定,以确定其作为针对固定化靶标的潜在活性分子。以固定化的EphB2受体酪氨酸激酶为靶标,并使用已知的激酶抑制剂,FAC-MS筛选结果(%位移)已被证明与结合常数K(d)以及传统ELISA检测得到的IC(50)结果相关。因此,由于FAC-MS能够适应多种靶蛋白,其应用不仅在活性分子发现阶段,而且在随后更严格的从活性分子到先导化合物以及先导化合物优化阶段的筛选过程中,都能在药物发现中发挥广泛作用。